Showing results (11-20 of 88) with videos related to
Sort By:
Pageof 9
Pharmacogenomics and Personalized Medicine|September 11, 2014
Simeprevir for the treatment of hepatitis C virus infectionLaure Izquierdo, François Helle, Catherine François, et al.Genes and Immunity|September 5, 2018
MICA and NKG2D variants as risk factors in spondyloarthritis: a case-control studyMarie Fechtenbaum, Judith Desoutter, Gauthier Delvallez, et al.Heliyon|December 7, 2023
Evaluation of the ABL NGS assay for HIV-1 drug resistance testingThomas Lhossein, Karine Sylvain, Véronique Descamps, et al.Antiviral Therapy|August 17, 2010
Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacyEtienne Brochot, Sandrine Castelain, Gilles Duverlie, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|July 26, 2015
Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian populationIkram Sghaier, Leila Mouelhi, Ezzedine Gazouani, et al.Cytokine|August 22, 2017
Role of TLRs and IL-6 in the outcome of chronic hepatitis C treatment in Tunisian populationIkram Sghaier, Leila Mouelhi, Ezzedine Ghazoueni, et al.Journal of Medical Virology|November 3, 2016
Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEASandra Bodeau, Jean-Philippe Lemouel, Momar Diouf, et al.Viruses|November 4, 2017
Biology of the BKPyV: An UpdateFrancois Helle, Etienne Brochot, Lynda Handala, et al.Journal of Clinical Medicine|April 30, 2021
Longitudinal Analysis and Comparison of Six Serological Assays up to Eight Months Post-COVID-19 DiagnosisAurélien Aubry, Baptiste Demey, Catherine François, et al.Antiviral Therapy|August 24, 2007
Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivityEtienne Brochot, Gilles Duverlie, Sandrine Castelain, et al.Pageof 9